In the context of Tau based therapies in PD, the inhibitors of GSK-3β (L803-mt and AR-A014418) reduced Tau phosphorylation and spared dopaminergic neurons from cell death in mesencephalic cultures [167,168]. This evidence concerns the gene MAPT and Parkinson disease.